Login / Signup

Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Soo Heon KwakKyung Ah HanKyung-Soo KimJae Myung YuEunSook KimJong Chul WonJun Goo KangChoon Hee ChungSeungjoon OhSung Hee ChoiKyu Chang WonSin Gon KimSeung Ah ChoBo Young ChoKyong Soo Park
Published in: Diabetes, obesity & metabolism (2023)
Monotherapy with enavogliflozin 0.3 mg improved glycaemic control in people with T2DM. Enavogliflozin therapy also exerted beneficial effects on body weight, blood pressure, and lipid profile. This article is protected by copyright. All rights reserved.
Keyphrases